Table 2.
Predictors of inpatient specialty palliative care consultation.
| Original model∗ |
90-day mortality subcohort∗ |
ACLF-3 subcohort∗ |
||||
|---|---|---|---|---|---|---|
| Variable | OR (95% CI) | p value∗∗ | OR (95% CI) | p value∗∗ | OR (95% CI) | p value∗∗ |
| Age (per year) | 1.03 (1.03-1.04) | <0.001 | 1.01 (1.01-1.02) | <0.001 | 1.01 (1.01-1.02) | <0.001 |
| Male sex | — | — | — | — | 0.66 (0.45-0.96) | 0.03 |
| BMI (per 5 unit change) | 0.93 (0.90-0.95) | <0.001 | 0.95 (0.92-0.98) | 0.005 | 0.95 (0.90-1.00) | 0.04 |
| MELD-Na | 1.02 (1.02-1.03) | <0.001 | — | — | — | — |
| Albumin (per 1 unit change) | 0.69 (0.65-0.74) | <0.001 | — | — | — | — |
| WBC count (per 5 unit change) | 1.05 (1.02-1.08) | 0.001 | 1.04 (1.01-1.08) | 0.02 | — | — |
| ACLF grade | ||||||
| 1 | (ref) | (ref) | — | — | ||
| 2 | 1.83 (1.67-2.00) | <0.001 | 1.49 (1.33-1.68) | <0.001 | — | — |
| 3 | 3.10 (2.79-3.44) | <0.001 | 1.56 (1.39-1.75) | <0.001 | — | — |
| Prior palliative care consultation | 2.44 (2.19-2.72) | <0.001 | 1.43 (1.26-1.62) | <0.001 | 1.51 (1.23-1.86) | <0.001 |
| Hepatocellular carcinoma | 2.21 (1.99-2.46) | <0.001 | 1.78 (1.57-2.02) | <0.001 | 1.32 (1.09-1.60) | 0.005 |
| High CIRCOM score | 0.72 (0.66-0.78) | <0.001 | 0.95 (0.86-1.05) | 0.30 | 0.79 (0.69-0.91) | 0.001 |
| Prior history of decompensated cirrhosis | 1.15 (1.06-1.24) | 0.001 | — | — | — | — |
| Prior TIPS | 0.64 (0.52-0.79) | <0.001 | — | — | — | — |
ACLF, acute-on-chronic liver failure; CIRCOM, cirrhosis comorbidity score; MELD-Na, model for end-stage liver disease-sodium; TIPS, transjugular intrahepatic portosystemic shunt; WBC, white blood cell.
∗
Mixed-effects models, designating Veterans Affairs facility as a random intercept, were used to generate odds ratios and p values.
∗∗
Level of significance: p value <0.001.